Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of increasing prevalence marked by poor prognosis and limited treatment options. Ca 21 -activated K Ca 3.1 potassium channels have been shown to play a key role in the aberrant activation and responses to injury in both epithelial cells and fibroblasts, both considered key drivers in the fibrotic process of IPF. Pharmacological inhibition of IPF-derived fibroblasts is able to somewhat prevent TGF-b-and basic fibroblast growth factor-dependent profibrotic responses. In the current study, we investigated whether blockade of the K Ca 3.1 ion channel in vivo with a selective inhibitor, Senicapoc, was able to attenuate both histological and physiological outcomes of early fibrosis in our large animal (sheep) model for pulmonary fibrosis. We also determined whether treatment was targeting the profibrotic activity of sheep lung fibroblasts. Senicapoc was administered in established fibrosis, at 2 weeks after bleomycin instillation, and drug efficacy was assessed 4 weeks after treatment. Treatment with Senicapoc improved pre-established bleomycin-induced changes compared with vehicle control, leading to improved lung compliance, reduced extracellular matrix and collagen deposition, and a reduction in both a-smooth muscle actin expression and proliferating cells, both in vivo and in vitro.
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These studies show that inhibiting the K Ca 3.1 ion channel is able to attenuate the early fibrogenic phase of bleomycin-dependent fibrosis and inhibits profibrotic behavior of primary sheep lung fibroblasts. This supports the previous research conducted in human IPF-derived fibroblasts and suggests that inhibiting K Ca 3.1 signaling may provide a novel therapeutic approach for IPF.
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Clinical Relevance
Pulmonary fibrosis is a devastating disease with limited therapeutic options. Regulating activity of prime targets, such as fibroblasts with potassium/calcium channel blockers like Senicapoc, are an attractive novel therapy, as they are well tolerated and affordable. The current study provides additional in vivo evidence to support in vitro studies that blocking K Ca 3.1 in channels may be an effective means of treatment for pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a severe and fatal lung condition, characterized by rapid and progressive fibrosis within the lung interstitium (1) . Though it is considered an orphan disease, it currently affects over 5 million people worldwide, and disease incidence is increasing (2) .
Currently, the only treatments available for IPF, pirfendidone and nintedanib, are able to slow, but not halt, the rate of decline in patients with mild to moderate disease (3, 4) . In addition, the use of these drugs is associated with a side-effect profile that can result in discontinuation/noncompliance with many patients (5) . Therefore, there is a need to further develop therapies available to better target both the wider population and the progression of IPF.
Both epithelial cells and fibroblasts play critical roles in the regulation of injury and repair in the lung, and both have been shown to be key drivers in the fibrotic process of IPF (6, 7) . Both of these cell types rely on Ca 21 signaling for the regulation of many critical cellular functions (8) . Ca 21 -activated K 1 channels are one of the major mechanisms regulating the influx of external Ca 21 , which can be controlled through a variety of stimuli (8) . Ca 21 -activated K 1 channels open in response to increases in cytoplasmic Ca 21 ion concentrations, therefore maintaining a negative membrane potential and promoting further Ca 21 influx. Hence, they regulate a wide variety of cellular activities (9) . The intermediate conductance Ca 21 -activated K 1 channel, K Ca 3.1 (also KCNN4), is expressed in a number of different cell types, including both epithelial cells and fibroblasts (9) , and plays an important role in the regulation of cell proliferation, activation, migration, mediator release, and, importantly, wound healing (10) (11) (12) (13) . Though the ion channel is widely expressed in many tissues, previous research indicates that both pharmacological inhibition and genetic deletion of K Ca 3.1 in mice is able to prevent or attenuate several pathological conditions, including fibrosis (9). Importantly, these actions occur without adverse health consequences, making blockade of the K Ca 3.1 ion channel an attractive target.
To date, studies investigating the effects of K Ca 3.1 blockade in fibrosis have been promising. A recent study has demonstrated a role for the K Ca 3.1 ion channel in IPF, showing both increased expression and activity of the channel in IPF-derived lung myofibroblasts (10) , and that it regulates transforming growth factor (TGF)-b1-dependent effects in these cells (14, 15) . Importantly, pharmacological inhibition of these cells with K Ca 3.1-specific blockers attenuated profibrotic activity, such as proliferation, wound healing, collagen secretion, and growth factor-dependent contraction in vitro.
Senicapoc (also known as ICA-17043), the selective inhibitor of the K Ca 3.1 ion channel used in the aforementioned study, has previously been trialed in humans for other conditions (16) , including chronic asthma (17) , and has been demonstrated to be well tolerated and safe, with minimal side effects. We have previously used Senicapoc in a sheep model of asthma, which improved lung function in treated animals and was well tolerated (18) .
Animal models for the study of pulmonary fibrosis provide a useful tool to test novel therapies in an in vivo setting, although they have come under many levels of criticism in regard to their translational capabilities of mimicking the clinical setting (19) . We have developed a large animal model of pulmonary fibrosis in sheep, which uses a segmental bleomycin challenge regime to induce fibrosis in individual lobes of the animal (20, 21) . The use of sheep provides a lung with comparable structural and functional properties to human lungs, including elastance and compliance of the lung (22) , as well as the distribution and organization of extracellular matrix components. This makes sheep useful for investigating fibrotic remodeling and the subsequent impact of this on lung function in the parenchymal interstitium. As previously shown, this model demonstrates fibrotic remodeling within bleomycin-damaged lobes for at least 7 weeks, which correlates with impaired lung function in these lobes (21) , thus providing a durable fibrotic response to investigate novel therapies during a period of fibrosis and their effect on physiological factors.
In the current study, we investigated the in vivo effects of blocking K Ca 3.1 ion channel signaling with the inhibitor, Senicapoc, during the early fibrogenic response in our sheep model (20) . Specifically, we examined the impact that K Ca 3.1 blockade had on lung function, pathology, and collagen deposition (the basis of fibrosis) after bleomycin administration to induce fibrosis within specific lobes of the lungs. In addition, we performed in vitro studies using primary sheep lung fibroblasts to determine whether blockade of the ion channel had similar antifibrotic effects on this target cell, as previously demonstrated in human lung fibroblasts (10, 15) .
Materials and Methods
Detailed methods are described in the online supplement.
Sheep model of Pulmonary Fibrosis
A total of 20 female Merino sheep, aged approximately 1 year, were used in the study. Animals were housed indoors, and all procedures performed on the animals were approved by the Animal Experimentation Ethics Committee of the University of Melbourne (Parkville, VIC, Australia), which adheres to the Australian Code of Practice for the care and use of laboratory animals. Fibrosis was induced within specified regions of the lung of all treated animals, as indicated in Figure 1A , using pharmaceutical grade bleomycin sulfate (BLM; Hospira, Melbourne, VIC, Australia) at a concentration of 0.6 U bleomycin/ml saline, as previously described (21) , with two doses, 2 weeks apart. Sheep were killed at 7 weeks after BLM.
Administration of Senicapoc Treatment
Sheep were randomly assigned to either vehicle-or Senicapoc-treated groups, with 10 animals per group. At 2 weeks after the second BLM dose, sheep commenced treatment, and received either twice daily oral dosing of Senicapoc (30 mg/kg; Icagen Inc., Durham, NC) in vehicle solution, 0.5% methyl-cell MC (Sigma-Aldrich, Castle Hill, NSW, Australia) in distilled water, or vehicle alone, depending on treatment group.
Analysis of Segmental Lung
Segmental lung compliance was calculated as previously described (20) , using a custom-built segmental lung airway-monitoring system to monitor the segmental flow and pressure. A bronchoscope was wedged into an airway in the lung segment of interest and a constant flow (4.5 ml/s) of 5% CO 2 in air was passed through the working channel of the bronchoscope.
Histopathology
The differentially treated lung lobes from each sheep were processed for histological assessment using standard procedures from our laboratory (21) . The degree of fibrotic injury in lung parenchyma of each lobe was assessed by an experienced pathologist blinded to the treatment groups using a semiquantitative scoring system, as previously described (20) , using hematoxylin and eosin-stained sections. Masson's trichrome-stained slides were also quantified in a blinded fashion to give an indication of changes for overall extracellular matrix content within the parenchymal tissue using previously described methods, to give the fibrotic fraction of the tissue in each lobe (20) .
Collagen Concentration of Lungs
The hydroxyproline assay was used to extrapolate the collagen content and concentration of each segment, as described previously (23, 24) .
Immunohistochemistry
Immunohistochemistry was performed on frozen tissue of sheep lung tissue. Tissue sections were stained using previously described methods. Primary antibodies used were: anti-human KCNN4/K Ca 3.1 (rabbit polyclonal, 1:200; Lifespan Biosciences, Seattle, WA), anti-a-smooth muscle actin (a-SMA; mouse monoclonal, 1:800; SigmaAldrich), anti-human Ki-67 antibody (mouse polyclonal, 1:100; DAKO, Santa Clara, CA). For fluorescent staining, secondaries used were Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 594 goat anti-mouse IgG (both Abcam, Cambridge, UK). For peroxidase staining, goat antirabbit or mouse IgG (both Abcam) were used.
Cell Culture Isolation and Growth
Primary sheep lung fibroblast cultures were initiated from lung explants from normal sheep lungs by isolating an internal region of lower lung lobe from the surrounding tissue (n = 3 separate times), as previously described (25) . Cells were used between passages 5 and 6 for the described experiments.
Wound Healing Assay
Wound healing of sheep lung fibroblasts was assessed using scratch assay methods (n = 3 separate times) (10) . Cells were plated in 12-well plates in duplicates and grown to confluence. After quiescence, cells were treated with either media alone, 10% FBS plus 0 0.1% DMSO, in the presence or absence of 100 nM Senicapoc. An artificial wound was generated in monolayer and assessed at 0 and 24 hours.
Western Blot
Sheep lung fibroblasts were cultured in media or with TGF-b (1 ng/ml) in the presence or absence of Senicapoc for 72 hours. These cells were lysed and used for immunoblotting using the Odyssey Western blotting system (LI-COR Biosciences, Lincoln, NE) as previously described (25, 26) . The intensity of the bands was quantified using Image Studio Lite (LI-COR Biosciences).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism for Windows Version 6.0 (GraphPad Software Inc., La Jolla, CA). Each parameter was assessed for Gaussian distribution both visually and using the D'Agostino and Pearson omnibus normality test. Comparisons between individual lobes within the same sheep and comparisons of before and after treatment were performed using paired analyses. For normally distributed data, paired two-tailed t tests were used. Wilcoxon matched-pairs signed rank test was used for data that did not meet assumptions required for parametric testing. Differences between the Senciapoctreated sheep and control group (between lobes of different animals) were assessed using a Student's t test for data with a normal distribution and a Mann-Whitney test for data with a nonparametric To confirm that the ion channel was expressed within the sheep lung with a similar distribution to human lung (10), tissue from each differently treated lobe was stained with anti-K Ca 3.1 and anti-a-SMA antibodies. In both the saline vehicle-treated lobes and saline-Senicapoc-treated control lobes, there was strong immunostaining for K Ca 3.1 in airway epithelial cells and much weaker staining in alveolar epithelial cells ( Figure 2A ). In the BLM-damaged lobes without Senicapoc treatment, there was also strong expression in areas of damage/fibrosis, as indicated by positive a-SMA in parenchymal tissue, particularly in alveolar epithelial cells, in addition to the positive staining seen in the airway epithelial cells ( Figure 2B , asterisk). In these lobes, there also appeared to be some positive staining for both a-SMA and K Ca 3.1 antibodies in damaged parenchymal regions, suggesting expression of the ion channel in lung fibroblasts detectable in vivo ( Figure 2B , arrows). The extent and distribution of positive staining for the ion channel in BLM lobes treated with Senicapoc was similar to what was observed in control saline-treated lobes ( Figure 2C ).
Senicapoc Treatment Recovers the Loss of Pulmonary Function Associated with the Development of BLM-Dependent Pulmonary Fibrosis
Lung compliance was measured in each differentially treated lobe before the commencement of any treatments and throughout the study at the time points outlined in Figure 1B . There was no significant change in lung compliance throughout the trial for treatment with vehicle or Senicapoc only ( Figures 3A and  3C , respectively). As expected from our previous studies (21) , the lobes treated with BLM plus vehicle showed a continual loss of lung compliance from baseline values over the study, reaching significance from 4 weeks after BLM onward ( Figure 3B ). This effect was abrogated in BLM-treated lobes cotreated with Senicapoc. In these lobes, there was some loss of lung compliance seen at 2 weeks after BLM, at which point treatment with Senicapoc commenced. Throughout treatment, lung compliance increased from this initial loss observed at 2 weeks, and had returned to nearbaseline values by 7 weeks after BLM ( Figure 3D ). The percentage change in compliance at 7 weeks after BLM injury from pre-BLM values was compared between the BLM-injured lobes from both treatment groups, and shows that sheep that received Senicapoc treatment had significantly higher lung compliance, closer to baseline values, than sheep treated with vehicle control only ( Figure 3E ). This indicates that the K Ca 3.1 ion channel inhibitor was able to counteract the established functional decline of the lungs induced after bleomycin exposure.
Effect on K Ca 3.1 Inhibition on the BLM-Induced Fibrotic Response
To determine the in vivo antifibrotic effects of Senicapoc treatment in the BLM-induced lung fibrosis in the sheep model, we assessed histopathology, collagen deposition ( Figure 4) , and a-SMA immunohistochemistry staining in lung tissue ( Figure 5 ). As expected, BLM plus vehicle-treated lobes showed prominent changes to the alveolar wall, with increased septal thickness, patchy fibrotic lesions, some inflammatory cell infiltration, and hyperplasia of alveolar epithelial cells ( Figure 4B ), when compared with the saline control lobes. By contrast, the development of these features was reduced in animals treated with Senicapoc. These changes were confirmed by semiquantitative scoring of the pathology observed ( Figures 4E and  4F ). In particular, the degree of pulmonary fibrosis (indicated by an overall score [ Figure 4E ], and both individual fibrosis ( Figure 4F ) and inflammatory component scores [ Figure 4G ]) in the BLM-vehicle group was significantly higher than that measured from the saline-treated lobes. showed a drop from baseline compliance at 2 weeks, which decreased further at 4 weeks and 7 weeks, and these were significantly lower than baseline. (C) Saline lobes that received Senicapoc (Sal-Sen) treatment showed no significant change at any time point. (D) BLM-treated lobes that received Senicapoc (BLM-Sen) showed a drop in compliance from baseline at 2 weeks, at which point treatment commenced, and compliance increased over the remaining time points back to levels comparable to baseline. (E) A comparison of the two lobes, which were injured with BLM, as a percentage change at 7 weeks after BLM from pre-BLM baseline. There is a significant increase in the lung compliance in the sheep that received Senicapoc compared with the sheep treated with vehicle control only. Significance was determined using paired t tests between lobes from the same treatment group and unpaired t tests between lobes from different groups. Data represent mean (6SEM). **P , 0.01, *P , 0.05. Baseline, before any treatment (saline, or BLM); Week 2, first dose of Senicapoc or vehicle. Cseg, segmental compliance. Significance was determined using paired t test between lobes from the same treatment group and unpaired t test between lobes from different groups, ****P , 0.0001 Sal-veh versus BLM-veh; ***P , 0.001 sal-veh versus BLM-veh; **P , 0.01 Sal-veh versus BLM-veh and BLM-veh versus BLM-sen; ## P , 0.01 BLM-veh versus BLM-sen. Data represent mean (6SEM). Scale bars, 200 mm (left panels) and 100 mm (right panels).
ORIGINAL RESEARCH
Importantly, sheep that received the K Ca 3.1 inhibitor had significantly lower scores in the BLM-treated lobes compared with BLM-vehicle-treated lobes (Figures 4E-4G ). Both Masson's trichrome staining of lung sections ( Figures 4A-4C ) and hydroxyproline analysis of total lung collagen concentration ( Figure 4I ) were used to confirm the changes to extracellular matrix/collagen deposition in the lung. There was a significant reduction in extracellular matrix staining induced by BLM in the sheep treated with Senicapoc ( Figure 4H ). Hydroxyproline analysis of total lung collagen concentration also showed that there appeared to be a reduction in total collagen concentration in the lung in Senicapoc-treated sheep when compared with BLM lobes in control sheep; however, this did not reach statistical significance. However, there was no longer any significant difference in collagen concentration between saline-treated versus BLM-Senicapoc-treated lung lobes.
In addition to pathology scoring, we examined the fibrotic response to BLM treatment by staining lung tissue sections with an anti-a-SMA antibody, a commonly used marker for activated fibroblasts (27) . Consistent with our previous studies (21), we found that BLM treatment in the vehicle control group substantially increased a-SMA content when compared with the corresponding saline-treated lobes, with prominent immunostaining observed in the alveolar walls of fibrotic lesions ( Figures 5A and 5B ). Senicapoc treatment significantly reduced the density of activated myofibroblasts induced by BLM, suggesting that myofibroblast recruitment and/or differentiation was attenuated. Quantitative assessment of the tissue stained with a-SMA antibody showed that there was a greater than 40% reduction in a-SMA staining in BLM-Senicapoc-treated lobes when compared with the BLM-vehicle lobes ( Figure 5C , P = 0.008, n = 10 per group).
To clarify the mechanisms by which Senicapoc treatment reduced BLM-induced fibrotic changes, we assessed whether treatment inhibited cell proliferation in vivo. Lung sections stained with an anti-Ki-67 antibody, a cellular marker for proliferation, revealed that the number of positive cells was significantly increased in response to BLM damage and was more frequently observed, predominantly in fibrotic lesions, but not in normal alveolar spaces ( Figure 6B ). Interestingly, Senicapoc treatment markedly decreased the BLM-induced increase in Ki-67-postivie cells within the lung (Figure 6D ), indicating an inhibition of cell proliferation by Senicapoc in response to BLM injury. Ki-67-positive cells were rarely observed in saline-treated lobes ( Figures 6A and 6C ). Data show individual value plus mean, n = 10 (each lobe). Significance was determined using paired t test between lobes from the same treatment group and unpaired t test between lobes from different groups, ****P , 0.0001 and **P , 0.001 Sal-veh versus BLM-veh, and BLM-veh versus BLM-sen. Data represent mean (6SEM). Scale bars, 100 mm.
Antifibrotic Effects of Senicapoc Treatment on Sheep Lung Fibroblasts
We wanted to investigate whether the protective properties of Senicapoc treatment against BLM-induced fibrosis were a result of its antifibrotic effects. To do this, we assessed the response of primary sheep lung fibroblasts to Senicapoc treatment, as had previously been demonstrated in both normal and IPF-derived human lung fibroblasts (10, 14, 15) .
First, we confirmed the expression of the K Ca 3.1 protein expression in sheep lung fibroblasts by Western blot (n = 3, Figure 7A ). Next, we investigated whether K Ca 3.1 regulated the transdifferentiation of fibroblasts to the active myofibroblast phenotype by assessing the expression of a-SMA in sheep lung fibroblasts, as previously described in human cells. Cells were stimulated for 72 hours with 1 ng/ml TGF-b in the presence or absence of 100 nM Senicapoc, and the expression of a-SMA was assessed in cell lysates by Western blot. We found that Senicapoc treatment was able to significantly reduce TGF-b-induced a-SMA in sheep lung fibroblasts (n = 3, Figure 7B ).
Previous studies conducted in human lung fibroblasts demonstrate a role of K Ca 3.1 in regulating fibroblast proliferation and migration. To confirm whether the antiproliferative effect observed in vivo was occurring in the sheep fibroblasts, the wound-healing response of these cells was assessed using a two-dimensional scratch assay ( Figure 7C ). Cells stimulated with 10% FBS plus 0.1% DMSO showed enhanced wound repair compared with media alone, but this was attenuated in presence of Senicapoc (100 nM), equivalent to inhibition of the FBS-dependent response by 32.5 (64.9)% (n = 3, Figure 7D ).
Discussion
The current evidence supporting the importance of the K Ca 3.1 channel and Ca 21 signaling in profibrotic and wound-healing responses in the lungs is based on in vitro studies (10, 12, 14) , yet there is no reported work that has investigated whether these findings translate in vivo in a therapeutic setting. Therefore, we sought to determine the efficacy of inhibiting the K Ca 3.1 ion channel in a more clinically relevant setting using delayed administration of Senicapoc, a selective inhibitor of K Ca 3.1, after resolution of the early inflammatory response to bleomycin in our large animal (sheep) model for pulmonary fibrosis (20, 21) . In this study, we have demonstrated that oral administration of Senicapoc improved lung function, ameliorated BLMinduced fibrosis, and attenuated profibrotic responses in primary sheep lung fibroblasts.
The initial research that explored the potential role for K Ca 3.1 in IPF revealed the presence of functional K Ca 3.1 channels within human lung myofibroblasts. In particular, myofibroblasts derived from IPF . An immunohistological analysis of the Ki-67 antibody, a cell proliferation marker, was performed on frozen lung sections from the differentially treated lung lobe: Ki-67-positive nuclei were seldom observed in the lung tissue from either saline-treated lobe (A and C). In response to BLM, there were many proliferating cells in fibrotic lesions in response to BLM injury ([B] indicated by arrows), but were not present in BLM-exposed lobes in sheep that were treated with Senicapoc (D).
No staining was seen in the antibody isotype negative control (E). A semiquantitative analysis confirmed that the number of Ki-67-positive cells was increased in the fibrotic lesions in response to BLM injury alone but was reduced with Senicapoc treatment (F). Data are individual values plus means, n = 10 (each lobe). Significance was determined using paired t test between lobes from the same treatment group and unpaired t test between lobes from different groups. ***P , 0.001 Sal-veh versus BLM-veh, ## P , 0.01 BLM-veh versus BLM-sen. Data represent mean (6SEM). Scale bars, 100 mm.
lung had increased ion channel expression and activity when compared with normal lung myofibroblasts (10). Importantly, in vitro studies also demonstrated that pharmacological inhibition of K Ca 3.1 by the selective blockers, (1-[(2-Chlorophenyl) diphenylmethyl]-1H-pyrazole) (TRAM-34) and Senicapoc, attenuates the profibrotic behavior of human lung myofibroblasts, both at rest and after TGF-b1-dependent stimulation (10, 14, 15) . Although this work provides critical mechanistic insight into the inhibitory effects of K Ca 3.1 blockers at a cellular level, it is important to further evaluate the effect of inhibitors, such as Senicapoc, within an in vivo setting to determine whether there is a pathophysiological effect. This is important, as to improve and slow decline in lung function are currently the major endpoints in clinical trials for IPF to determine drug efficacy (28) .
In the present study, we found that administration of Senicapoc during the early fibrogenic response to BLM injury was effectively able to reverse lung function loss, close to the healthy levels that were observed before the commencement of the study. As we have previously shown in our model that the effects of BLM on lung compliance are maintained for at least 7 weeks after BLM (21) , and lung function was still significantly impaired in the control group, we feel confident that the restoration of lung compliance back to near-normal levels after Senicapoc administration is not due to natural resolution, but is a result of drug treatment. To our knowledge, there are no other studies that have investigated the effects of Senicapoc on lung function caused by fibrosis. We have previously shown that a similar dosing regimen to the one used in the current study was able to attenuate allergen-induced airway responses in our sheep model for chronic asthma (18) . Drug treatment did not affect the overall health of the animals in either study, signifying that the protocol for administration is effective on physiological outcomes, without having deleterious side effects. Along with the improvements observed in lung function seen in response to treatment with the K Ca 3.1 ion channel inhibitor, there was also a corresponding improvement in BLM-induced fibrotic injury seen in animals that received Senicapoc. In the current study, we found that Senicapoc administered during the early fibrogenic phase (2 wk after injury, with prominent fibrosis and collagen deposition, as previously shown in this model [20] ) reversed this. Sheep that received Senicapoc had minimal fibrosis within alveolar walls and reduced lung collagen content in BLM-exposed lobes. By contrast, BLM-damaged lobes in the control group still had significant pathology at the end of the study, as we have previously shown in our model (21) . This indicates that the improvements with Senicapoc treatment can be attributed to the effects of blocking K Ca 3.1, rather than natural resolution of the fibrosis that is sometimes observed in other animal models of pulmonary fibrosis (29) .
Although this study aimed to target fibrogenic events in response to BLM injury, it is important to note that there are still some inflammatory events occurring at the time of Senicapoc administration, as shown in our earlier studies (20) . The use of K Ca 3.1 inhibitors, including Senicapoc, has been previously shown to have both antiinflammatory, as well as antifibrotic properties in allergic asthma (30) . Therefore, it is possible that Senicapoc treatment in the current study may be directed against ongoing inflammation and fibrosis.
It is well established that fibroblasts play an essential role in the ongoing propagation of fibrosis in IPF. Therefore, we chose to assess the response of primary sheep lung fibroblasts to better clarify whether Senicapoc treatment was targeting this key effector cell and have an inhibitory effect on profibrotic activity, as previously demonstrated in human lung fibroblasts. We were able to show that inhibition of the K Ca 3.1 ion channel attenuated TGF-b-induced a-SMA production in these cells, supporting the previous in vitro studies. Those studies also demonstrated that TGF-b1-dependent increases in a-SMA and collagen type I in human lung fibroblasts from patients with IPF were blocked at both mRNA and protein levels with either TRAM-34 or Senicapoc (14, 15) . Furthermore, this is supported by the reduction in a-SMA staining in BLM lobes in the Senicapoctreated sheep, suggesting a reduction in active fibroblasts occurring in vivo. In the animal model, we also observed reduced collagen content and concentration in the BLM-treated lobes in sheep receiving Senicapoc, suggesting that this may be a result of decreased collagen production from the fibroblasts. Although we did not assess the collagen production in the sheep lung fibroblasts, the diminished a-SMA content in the fibroblasts from human lungs through inhibition of TRAM-34 or Senicapoc was accompanied by reduced collagen secretion and contraction of these cells (10) , therefore it is likely that the sheep lung fibroblast also show reduced collagen secretion.
Although we have not explored the exact pathways that are being targeted in the sheep lung fibroblasts to result in a downregulation of a-SMA, research conducted in human lung fibroblasts has also demonstrated that the inhibition of K Ca 3.1 channels interferes with the TGF-b1/Smad signaling pathway (14, 15) . This pathway is critical in the regulation of a-SMA expression and stress fiber formation in fibroblasts and subsequent functional behavior, such as collagen secretion, proliferation, differentiation, and contraction. In human lung fibroblasts, constitutive Smad2/3 nuclear translocation in response to TGF-b stimulation was inhibited after blockade of K Ca 3.1, resulting in a reduction in a-SMA expression (14, 15) . It would be useful to conduct studies investigating whether this was also occurring in the sheep lung fibroblasts, or if other pathways were targeted.
The K Ca 3.1 ion channel appears to regulate the TGF-b1/Smad signaling pathway through the inhibition of extracellular Ca 21 influx (14) , which, in turn, regulates behavioral functions of the cell, including proliferation and migration (10, 17) . Proliferation of fibroblasts and myofibroblasts in IPF and other fibrosing lung diseases is a key pathological event that contributes to expansion of this cell population. Inhibition of the K Ca 3.1 ion channel reduces cell proliferation and migration in human myofibroblasts in response to FBS (10) , which was also observed in the current study using sheep lung fibroblasts. This antiproliferative effect of Senicapoc was also exhibited in vivo using the BLM sheep model. Together, this suggests that key fibrotic events are being targeted in vivo with Senicapoc treatment.
The results from the current study highlight that the beneficial effects observed with treatment of Senicapoc against BLMinduced fibrosis in sheep is occurring, in part, through the attenuation of profibrotic fibroblast activity (10, 14, 15) . However, it is also likely that Senicapoc elicits a similar effect on alveolar epithelial cells. There is additional research showing that K Ca 3.1 regulates proliferation of alveolar epithelial cells after injury, and blocking activity of the channel both pharmacologically or with gene silencing decreased the growth of these cells (12) .
In the current study, immunohistochemistry revealed that sheep lobes from the BLM-injured sheep showed more marked K Ca 3.1 expression within the alveolar epithelial cells of damaged/fibrotic regions, which aligns with the pattern observed in human IPF lung tissue. Interestingly, this expression was not observed in BLM-damaged lobes of sheep receiving the ion channel inhibitor, Senicapoc, which instead tended to resemble the staining seen in saline-treated control lobes. This result is not surprising, as there is evidence that the ion channel is able to regulate its own mRNA expression (14) , which presumably would be translated to subsequent protein expression. In human lung myofibroblasts, K Ca 3.1 mRNA and functional channel expression are up-regulated by TGF-b1 via a rise in intracellular Ca 21 , which promotes Smad2/3 phosphorylation and nuclear translocation, and subsequent activation of TGF-b1-dependent gene transcription (14) . This included TGF-b1-dependent increases in K Ca 3.1 expression and, importantly, K Ca 3.1 inhibition of the downregulation of K Ca 3.1 mRNA expression (14) . As BLM-induced injury increased TGF-b1 expression, as also shown in our previous work (20, 21) , this would suggest that BLM can drive TGF-b1-dependent increases in K Ca 3.1 expression, and that this process can be regulated through the use of specific inhibitors. However, further work evaluating mRNA and protein levels of the K Ca 3.1 ion channel in response to BLM administration would be required to confirm this.
It is important to highlight that we have demonstrated the effects of K Ca 3.1 inhibition during the more fibrotic phase of injury. Therefore, this represents a more "therapeutic" time frame for IPF than drug before or at the time of injury. In addition, the current study incorporates physiological parameters to evaluate the efficacy of the drug, which aligned more closely to endpoints used in clinical trials on patients with IPF (28) . An in-depth review published by Moeller and colleagues in 2008 (19) highlighted two crucial elements in the design of the models required to improve translational success. These were the use of clinically relevant assessment tools for determination of drug efficacy, and timing of drug application to distinguish between anti-inflammatory and antifibrotic drug-induced effects. Despite this review, many studies claiming to investigate the therapeutic or antifibrotic effects of novel compounds still fail to incorporate both of these elements, either administering the drug too early (parallel to BLM or 7 d after BLM during the inflammatory phase) (31, 32) or do not investigate lung functional parameters (33, 34) . Therefore, the results from the current study provide more reliable evidence for the antifibrotic capacity of specifically inhibiting the K Ca 3.1 ion channel. However, it is important to note that no animal model has yet to fully recapitulate the pathological process that occurs in IPF, and caution must still be taken when extrapolating results from this study back to humans.
In summary, we have demonstrated that inhibiting the K Ca 3.1 ion channel with orally administered Senicapoc attenuated BLM-induced pulmonary fibrosis in a sheep model and inhibited the profibrotic characteristics of sheep lung fibroblasts, as previously demonstrated in human normal and IPF-derived lung fibroblasts. In the animal model, we clearly demonstrated decreases in Senicapoc-induced pathology scores, aberrant collagen deposition, and its ability to restore the deleterious effects of BLM on lung function in a more therapeutic setting. In addition, Senicapoc treatment reduced the wound-healing response and TGF-b-induced a-SMA content of sheep lung fibroblasts, as observed in vivo. The results presented here strengthen the argument that targeting K Ca 3.1 may provide a novel and effective means of treatment for IPF. We provide the first in vivo evidence that inhibiting K Ca 3.1 not only prevents fibrosis, but also can reverse established fibrosis in lung tissue. If the same is true for human IPF, this would represent a major step change in the treatment of this devastating disease. Senicapoc was well tolerated with few side effects over 12 months in a phase III clinical trial of sickle cell disease (17) , so there is the potential to proceed rapidly to clinical trials of Senicapoc in human IPF. n
